Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant differences were observed between groups in phosphorus (p = 0.342), vitamin D (p = 0.449), or PTH levels (p = 0.653).

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Beyond Tumor Control in Sporadic Neuroendocrine Tumor: Metabolic and Bone Health During Treatment with Somatostatin Analogs

Study design awaiting verification · Journal of Clinical Medicine · 2026

Original publication title

Beyond Tumor Control in Sporadic Neuroendocrine Tumor: Metabolic and Bone Health During Treatment with Somatostatin Analogs

Roberta Modica; Alessia Liccardi; Roberto Minotta; Elio Benevento; Gianfranco Di Iasi; Massimo Di Nola; Michele Coletta; Colao Annamaria

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Somatostatin analogs (SSAs) are widely used in the treatment of neuroendocrine tumors (NETs). Despite SSAs having a favorable safety profile, their long-term impact on glucose metabolism and bone health remains uncertain. This study aimed to compare glycemic, calcium-phosphorus, and densitometric parameters between patients with sporadic NETs receiving SSA therapy and untreated patients.

Methods:

A retrospective observational study enrolling patients with sporadic NETs was conducted at Federico II University of Naples, Endocrinology Unit, ENETS Center of Excellence.

Results:

A total of 40 patients were enrolled: 18 (45%) treated with SSA (SSA+) and 22 (55%) untreated (SSA−). The median duration of SSA treatment was 24.5 months (range 12 to 180). HbA1c was significantly higher in the SSA+ group compared to SSA− (median 6.20% vs. 5.70%; p = 0.027). Corrected calcium levels were significantly lower in SSA+ patients (8.90 vs. 9.47 mg/dL; p = 0.045). No significant differences were observed between groups in phosphorus, vitamin D or PTH levels. Median lumbar T-score was −0.15 in SSA+ vs. −1.10 in SSA− (p = 0.256); lumbar BMD was 1.23 vs. 0.97 g/cm2 (p = 0.127). Femoral neck T-score was −0.85 vs. −1.55 and femoral BMD was 0.89 vs. 0.78 g/cm2. The prevalence of osteoporosis and osteopenia did not differ significantly between groups. Within the SSA+ group, treatment duration showed no significant correlations with any densitometric parameter.

Conclusions:

SSA treatment in patients with sporadic NETs is associated with a significant impairment of glycemic control. The reduction in serum calcium observed in SSA+ patients may indicate an indirect effect on calcium-phosphorus metabolism that warrants further investigation. These findings support careful metabolic assessment during follow-up. Although routine densitometric evaluation based solely on SSA exposure does not appear warranted, bone health assessment may be considered according to individual skeletal risk factors and the patient’s overall clinical profile.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Somatostatin analogs (SSAs) are widely used in the treatment of neuroendocrine tumors (NETs). Despite SSAs having a favorable safety profile, their long-term impact on glucose metabolism and bone health remains uncertain. This study aimed to compare glycemic, calcium-phosphorus, and densitometric parameters between patients with sporadic NETs receiving SSA therapy and untreated patients.

Source: Background

Abstract: Results

A total of 40 patients were enrolled: 18 (45%) treated with SSA (SSA+) and 22 (55%) untreated (SSA−). The median duration of SSA treatment was 24.5 months (range 12 to 180). HbA1c was significantly higher in the SSA+ group compared to SSA− (median 6.20% vs. 5.70%; p = 0.027). Corrected calcium levels were significantly lower in SSA+ patients (8.90 vs. 9.47 mg/dL; p = 0.045). No significant differences were observed between groups in phosphorus, vitamin D or PTH levels. Median lumbar T-score was −0.15 in SSA+ vs. −1.10 in SSA− (p = 0.256); lumbar BMD was 1.23 vs. 0.97 g/cm2 (p = 0.127). Femoral neck T-score was −0.85 vs. −1.55 and femoral BMD was 0.89 vs. 0.78 g/cm2. The prevalence of osteoporosis and osteopenia did not differ significantly between groups. Within the SSA+ group, treatment duration showed no significant correlations with any densitometric parameter.

Source: Results

Abstract: Conclusions

SSA treatment in patients with sporadic NETs is associated with a significant impairment of glycemic control. The reduction in serum calcium observed in SSA+ patients may indicate an indirect effect on calcium-phosphorus metabolism that warrants further investigation. These findings support careful metabolic assessment during follow-up. Although routine densitometric evaluation based solely on SSA exposure does not appear warranted, bone health assessment may be considered according to individual skeletal risk factors and the patient’s overall clinical profile.

Source: Conclusions
Authors’ abstract

Simple Summary

Neuroendocrine tumors are uncommon tumors that frequently require prolonged treatment with somatostatin analogs, to control tumor growth and hormone-related symptoms. Although these agents have a generally favorable safety profile, their long-term effects on glucose metabolism and skeletal health remain incompletely understood. This study compared metabolic and bone parameters in patients with neuroendocrine tumors receiving somatostatin analogue therapy and in untreated patients, including glycemic control, calcium balance, and bone mineral density. Treated patients showed higher blood glucose levels and lower calcium levels than untreated patients, whereas bone density did not differ significantly between the two groups.

Notably, a substantial proportion of patients in both groups presented reduced bone density. Given the observational design and relatively limited sample size, these findings indicate associations rather than causal relationships. These findings highlight the importance of considering metabolic and skeletal health during the clinical follow-up of patients with neuroendocrine tumors, with bone assessment tailored to individual risk factors.

Abstract

Background:

Somatostatin analogs (SSAs) are widely used in the treatment of neuroendocrine tumors (NETs). Despite SSAs having a favorable safety profile, their long-term impact on glucose metabolism and bone health remains uncertain. This study aimed to compare glycemic, calcium-phosphorus, and densitometric parameters between patients with sporadic NETs receiving SSA therapy and untreated patients.

Methods:

A retrospective observational study enrolling patients with sporadic NETs was conducted at Federico II University of Naples, Endocrinology Unit, ENETS Center of Excellence.

Results:

A total of 40 patients were enrolled: 18 (45%) treated with SSA (SSA+) and 22 (55%) untreated (SSA−). The median duration of SSA treatment was 24.5 months (range 12 to 180). HbA1c was significantly higher in the SSA+ group compared to SSA− (median 6.20% vs. 5.70%; p = 0.027). Corrected calcium levels were significantly lower in SSA+ patients (8.90 vs. 9.47 mg/dL; p = 0.045). No significant differences were observed between groups in phosphorus, vitamin D or PTH levels. Median lumbar T-score was −0.15 in SSA+ vs. −1.10 in SSA− (p = 0.256); lumbar BMD was 1.23 vs. 0.97 g/cm2 (p = 0.127). Femoral neck T-score was −0.85 vs. −1.55 and femoral BMD was 0.89 vs. 0.78 g/cm2. The prevalence of osteoporosis and osteopenia did not differ significantly between groups. Within the SSA+ group, treatment duration showed no significant correlations with any densitometric parameter.

Conclusions:

SSA treatment in patients with sporadic NETs is associated with a significant impairment of glycemic control. The reduction in serum calcium observed in SSA+ patients may indicate an indirect effect on calcium-phosphorus metabolism that warrants further investigation. These findings support careful metabolic assessment during follow-up. Although routine densitometric evaluation based solely on SSA exposure does not appear warranted, bone health assessment may be considered according to individual skeletal risk factors and the patient’s overall clinical profile.

Publication and source details

Original title: Beyond Tumor Control in Sporadic Neuroendocrine Tumor: Metabolic and Bone Health During Treatment with Somatostatin Analogs

Roberta Modica; Alessia Liccardi; Roberto Minotta; Elio Benevento; Gianfranco Di Iasi; Massimo Di Nola; Michele Coletta; Colao Annamaria

Journal of Clinical Medicine · 2026

* Correspondence: roberta.modica@unina.it (R.M.); alessia.liccardi@yahoo.com (A.L.)
†

These authors contributed equally to this work.

© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:43:31.503800+00:00

DOI: 10.3390/jcm15176927 · PMC13566002